Liver function monitoring and management guidance during treatment with pazopanib

Pazopanib is an oral multi-target tyrosine kinase inhibitor mainly used for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. Since the drug is metabolized in the liver, one of the more common clinical side effects is abnormal liver function, manifested as elevated transaminase, elevated bilirubin, etc. Therefore, regular monitoring and management of liver function are of great significance to ensure the safety of patient treatment.

Before starting pazopanib treatment, patients should undergo a comprehensive liver function assessment, including detection of ALT, AST, total bilirubin, alkaline phosphatase and other indicators. If patients have abnormal liver function at baseline, they should carefully decide whether to use pazopanib and adjust the starting dose or choose other treatment options if necessary. For patients whose liver function has been clearly damaged, an individualized medication strategy should be developed after weighing the pros and cons.

During treatment, it is recommended to monitor liver function every two weeks in the first two months, and then recheck once a month, or the frequency can be flexibly adjusted according to the condition. If ALT or AST is found to be elevated more than 3 times the upper limit of normal and is accompanied by an increase in bilirubin, medication should be discontinued immediately and evaluated; if there is an asymptomatic mild increase, continued treatment may be considered while closely observing changes. In the event of severe hepatotoxicity, pazopanib should be permanently discontinued and supportive care should be given.
In addition to drug monitoring, patients should also avoid ingesting other substances that may increase the burden on the liver, such as alcohol, acetaminophen, etc. In addition, patients should be informed that they should seek medical attention immediately if they develop symptoms such as fatigue, loss of appetite, jaundice, or darker urine while taking the drug. With standardized liver function monitoring and timely intervention, most patients can use pazopanib safely while achieving good therapeutic effects.
Reference: https://www.votrient.com/